Biophytis, Sorbonne Université - BC9, 4 Place Jussieu, 75005 Paris, France.
Biophytis, Sorbonne Université - BC9, 4 Place Jussieu, 75005 Paris, France; Sorbonne Université, CNRS - Institut de Biologie Paris Seine (BIOSIPE), 75005 Paris, France.
Drug Discov Today. 2021 May;26(5):1311-1318. doi: 10.1016/j.drudis.2021.02.010. Epub 2021 Feb 17.
COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has reached pandemic proportions with negative impacts on global health, the world economy and human society. The clinical picture of COVID-19, and the fact that Angiotensin converting enzyme 2 (ACE2) is a receptor of SARS-CoV-2, suggests that SARS-CoV-2 infection induces an imbalance in the renin-angiotensin system (RAS). We review clinical strategies that are attempting to rebalance the RAS in COVID-19 patients by using ACE inhibitors, angiotensin receptor blockers, or agonists of angiotensin-II receptor type 2 or Mas receptor (MasR). We also propose that the new MasR activator BIO101, a pharmaceutical grade formulation of 20-hydroxyecdysone that has anti-inflammatory, anti-fibrotic and cardioprotective properties, could restore RAS balance and improve the health of COVID-19 patients who have severe pneumonia.
新型冠状病毒病（COVID-19）由严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）引起，已在全球范围内广泛流行，对全球健康、世界经济和人类社会造成负面影响。COVID-19 的临床表现以及血管紧张素转换酶 2（ACE2）是 SARS-CoV-2 的受体这一事实表明，SARS-CoV-2 感染会导致肾素-血管紧张素系统（RAS）失衡。我们综述了通过使用血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂或血管紧张素 II 受体型 2 或 Mas 受体（MasR）激动剂来尝试使 COVID-19 患者的 RAS 恢复平衡的临床策略。我们还提出，新型 MasR 激动剂 BIO101 是 20-羟基蜕皮甾酮的药物级配方，具有抗炎、抗纤维化和心脏保护特性，可能恢复 RAS 平衡并改善患有严重肺炎的 COVID-19 患者的健康状况。
